Page last updated: 2024-12-05

(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

**(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride** is a chemical compound with a complex structure, and it's important to break down its parts to understand its potential applications.

**Structure Breakdown:**

* **(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)**: This part refers to a specific organic molecule with a chain of four carbon atoms (butyne) and a triple bond between the second and third carbon. The m-chlorophenylcarbamoyloxy group is attached to the fourth carbon.
* **Trimethylammonium chloride**: This part refers to a positively charged quaternary ammonium ion with three methyl groups attached to nitrogen. The chloride anion balances the positive charge.

**Potential Importance in Research:**

The exact applications of this compound are not readily available through a simple search. However, considering the structural features, it could potentially be relevant in several research areas:

* **Pharmacology:** The presence of the m-chlorophenyl group suggests potential biological activity. This group is commonly found in pharmaceuticals and can interact with various biological targets.
* **Materials Science:** The triple bond in the butyne chain and the quaternary ammonium ion could confer unique properties like surface activity or ability to form polymers.
* **Organic Chemistry:** The compound could be a valuable building block or intermediate for synthesizing other complex molecules with potential applications in diverse fields.

**To determine the specific research relevance, you would need more information about the context:**

* **What is the purpose of the study?**
* **What are the specific properties of the compound being investigated?**
* **How is the compound being used in the research?**

**It is crucial to note that:**

* This compound is not a common or well-studied compound, so information about its specific applications might be limited.
* The presence of a complex structure doesn't automatically guarantee importance or specific applications.

To find more detailed information about this compound, you would need to consult specialized scientific databases or contact researchers working in relevant fields.

(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride: A drug that selectively activates certain subclasses of muscarinic receptors and also activates postganglionic nicotinic receptors. It is commonly used experimentally to distinguish muscarinic receptor subtypes. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5926
SCHEMBL ID2977744
MeSH IDM0013150

Synonyms (50)

Synonym
ammonium, (4-hydroxy-2-butynyl)trimethyl-, chloride, m-chlorocarbanilate
mcn a-343 chloride
mcn a-343
butyl-1-aminium, 4-((((3-chlorophenyl)amino)carbonyl)oxy)-n,n,n-trimethyl-, chloride
(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride
carbanilic acid, m-chloro-, ester with (4-hydroxy-2-butynyl)trimethylammonium chloride
a 343
2-butyn-1-aminium, 4-((((3-chlorophenyl)amino)carbonyl)oxy)-n,n,n-trimethyl-, chloride
gtpl290
EU-0100277
mcn-a-343
smr000058673
MLS000859939
NCGC00093733-01
(4-hydroxy-2-butynyl)-1-trimethylammonium-m-chlorocarbanilate chloride
C 7041
55-45-8
4-[(3-chlorophenyl)carbamoyloxy]but-2-ynyl-trimethylazanium chloride
HMS3260H16
HMS2235M19
unii-cw55r761re
4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride
cw55r761re ,
LP00277
HMS3372P11
(4-hydroxy-2-butynyl)trimethylammonium chloride, m-chlorocarbanilate
a-343
2-butyn-1-aminium, 4-((((3-chlorophenyl)amino)carbonyl)oxy)-n,n,n-trimethyl-, chloride (1:1)
mcn-343
4-(m-chlorophenylcarbamoyloxy)-2-butynyltrimethylammonium chlori
mcn-a-343-11
CCG-221581
NCGC00260962-01
tox21_500277
mcn-a 343
4-[[[(3-chlorophenyl)amino]carbonyl]oxy]-n,n,n-trimethyl-2-butyn-1-aminium chloride
SCHEMBL2977744
AKOS024456563
DTXSID80203532
4-(n-[3-chlorophenyl]-carbamoyloxy)-2-butynyltrimethylammonium chloride
SR-01000075310-1
sr-01000075310
Q27083728
4-(((3-chlorophenyl)carbamoyl)oxy)-n,n,n-trimethylbut-2-yn-1-aminium chloride
4-(((3-chlorophenyl)carbamoyl)oxy)-n,n,n-trimethylbut-2-yn-1-aminiumchloride
(4-hydroxy-2-butynyl)-1-trimethylammonium-3-chlorocarbanilate chloride
MS-24679
4-[(3-chlorophenyl)carbamoyloxy]but-2-ynyl-trimethylazanium;chloride
CS-0029051
HY-107648

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Bell-shaped log dose-response curves were obtained for McN."( A comparative study of the effects induced by MCN-A-343 and acetylcholine on the isolated toad rectus abdominis.
Corrado, AP; Jurkiewicz, A; Simioni, LR, 1976
)
0.26
" Low concentrations of pirenzepine (10(-8) M), produced a rightward shift in the dose-response curve to McN, without inhibiting responses to carbachol."( Functional subtyping of muscarinic receptors on canine esophageal mucosa.
Donoff, B; Lad, R; Rangachari, PK, 1991
)
0.28
" McN A343 significantly reduced the cholinergic phase of the neurally evoked response and caused a rightward shift of the carbachol dose-response curve."( Muscarinic receptor subtypes mediating the mucosal response to neural stimulation of guinea pig ileum.
Carey, HV; Cooke, HJ; Tien, XY; Wallace, LJ, 1987
)
0.27
" The shifts caused by atropine and pirenzepine in the dose-response curves for ACh were not parallel after in vitro treatment of the muscle with DFP."( Contractile responses of tracheal smooth muscle in organophosphate-treated swine: 2. Effects of antagonists.
Dwyer, TM; Farley, JM; Murali Mohan, P; Yang, CM, 1988
)
0.27
" Analysis of the dose-response curves for contraction and inositol phosphates accumulation with these agonists demonstrated a direct relationship between the two parameters, with a considerable reserve of inositol phosphate production for the full contractile agonists, methacholine and oxotremorine, and no reserve for the partial agonist, McN-A-343."( Evidence for a direct relationship between phosphoinositide metabolism and airway smooth muscle contraction induced by muscarinic agonists.
Elzinga, CR; Kauffman, HF; Meurs, H; Postema, JB; Roffel, AF; Timmermans, A; Zaagsma, J, 1988
)
0.27
" Atropine caused a dose-dependent rightward shift in the dose-response curves of inhibitory and excitatory effects of the two muscarinic agonists."( Pharmacologic identification, activation and antagonism of two muscarine receptor subtypes in the lower esophageal sphincter.
Gilbert, R; Goyal, RK; Rattan, S, 1984
)
0.27
" The dose-response curves for SNI-2011 were approximately parallel to curves for pilocarpine but the potency of SNI-2011 was about 25-fold lower than that of pilocarpine."( Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjörgen's syndrome.
Iwabuchi, Y; Masuhara, T, 1994
)
0.29
" In the presence of chlorisondamine, McN-A-343 increased both RNA and BP in dose-related fashion, and the dose-response curves of McN-A-343 shifted to the right in the presence of pirenzepine."( Role of muscarinic receptors in ganglionic transmission in rabbits.
Kim, JH; Ro, YB, 1996
)
0.29
" Sigmoid dose-response curves were plotted, and the IC50s were calculated."( Comparison of the effects of M1 and M2 muscarinic receptor activation in the absence of GABAergic inhibition in immature rat hippocampal CA3 area.
Beaucher, J; Harnois, C; Psarropoulou, C, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
endonuclease IVEscherichia coliPotency11.22020.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency13.89340.100020.879379.4328AID588453
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency25.11890.540617.639296.1227AID2364; AID2528
lamin isoform A-delta10Homo sapiens (human)Potency4.46680.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki3.23590.00000.690210.0000AID1181731; AID454115
Muscarinic acetylcholine receptor M4Homo sapiens (human)Ki9.12010.00000.79519.1201AID1181733; AID454117
Muscarinic acetylcholine receptor M5Homo sapiens (human)Ki3.80190.00000.72926.9183AID1181734; AID454118
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki1.94980.00000.59729.1201AID1181730; AID454114
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki2.39880.00000.54057.7600AID1181732; AID454116
Muscarinic acetylcholine receptorCavia porcellus (domestic guinea pig)Ki3.80190.00010.61203.8019AID454118
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (39)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (72)

Assay IDTitleYearJournalArticle
AID1072501Agonist activity at muscarinic M1 receptor in New Zealand rabbit vas deferens assessed as stimulation of electrically-induced response2014European journal of medicinal chemistry, Mar-21, Volume: 75Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity.
AID141094In vitro binding affinity for muscarinic receptor by displacing [3H]oxotremorine-M binding on rat brain homogenate.1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity.
AID1181732Displacement of [3H]NMS from human muscarinic M3 receptor transfected in CHO cells after 120 mins by scintillation counting analysis2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Mode of interaction of 1,4-dioxane agonists at the M2 and M3 muscarinic receptor orthosteric sites.
AID302033Binding affinity to muscarinic M1 receptor in electrically stimulated New Zealand rabbit vas deferens2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Novel oxotremorine-related heterocyclic derivatives: Synthesis and in vitro pharmacology at the muscarinic receptor subtypes.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID231289Ratio of binding affinity at [3H]quinuclidinyl benzilate binding on rat brain stem homogenate to [3H]-Piperazine binding on rat brain homogenate1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity.
AID141560In vitro binding affinity against muscarinic acetylcholine receptor M1 from rat hippocampus, using [3H]pirenzepine (Pz) as radioligand1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .
AID302024Agonist activity at muscarinic M1 receptor in electrically stimulated New Zealand rabbit vas deferens2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Novel oxotremorine-related heterocyclic derivatives: Synthesis and in vitro pharmacology at the muscarinic receptor subtypes.
AID454118Displacement of [3H]NMS from human muscarinic M5 receptor expressed in CHO cells by microplate scintillation counting2009Bioorganic & medicinal chemistry, Dec-15, Volume: 17, Issue:24
Properly substituted 1,4-dioxane nucleus favours the selective M3 muscarinic receptor activation.
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID1181731Displacement of [3H]NMS from human muscarinic M2 receptor transfected in CHO cells after 120 mins by scintillation counting analysis2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Mode of interaction of 1,4-dioxane agonists at the M2 and M3 muscarinic receptor orthosteric sites.
AID142724In vitro binding affinity for muscarinic M1 receptor by displacing [3H]pirenzepine binding on rat brain homogenate.1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity.
AID166483In vitro inhibition of maximum twitch height in electrically stimulated rabbit vas deferens.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .
AID231288Ratio of binding affinity at [3H]quinuclidinyl benzilate binding on rat brain homogenate to [3H]- Oxotremorine-M binding on rat brain homogenate1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity.
AID454114Displacement of [3H]NMS from human muscarinic M1 receptor expressed in CHO cells by microplate scintillation counting2009Bioorganic & medicinal chemistry, Dec-15, Volume: 17, Issue:24
Properly substituted 1,4-dioxane nucleus favours the selective M3 muscarinic receptor activation.
AID141093In vitro binding affinity for muscarinic receptors by displacing [3H]quinuclidinyl benzilate binding on rat brain stem homogenate.1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity.
AID1181734Displacement of [3H]NMS from human muscarinic M5 receptor transfected in CHO cells after 120 mins by scintillation counting analysis2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Mode of interaction of 1,4-dioxane agonists at the M2 and M3 muscarinic receptor orthosteric sites.
AID141092In vitro binding affinity for muscarinic receptors by displacing [3H]quinuclidinyl benzilate binding on rat brain homogenate1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity.
AID1181736Agonist activity at New Zealand white rabbit vas deferens muscarinic M1 receptor2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Mode of interaction of 1,4-dioxane agonists at the M2 and M3 muscarinic receptor orthosteric sites.
AID454115Displacement of [3H]NMS from human muscarinic M2 receptor expressed in CHO cells by microplate scintillation counting2009Bioorganic & medicinal chemistry, Dec-15, Volume: 17, Issue:24
Properly substituted 1,4-dioxane nucleus favours the selective M3 muscarinic receptor activation.
AID140990In vitro ability to contract isolated guinea pig ileum was used to estimate M2/M3 agonist effect1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1072495Inhibition of acetylcholinesterase in rat brain homogenate after 15 mins by Ellman assay2014European journal of medicinal chemistry, Mar-21, Volume: 75Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity.
AID1181735Agonist activity at New Zealand white rabbit vas deferens muscarinic M1 receptor relative to McN-A-3432014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Mode of interaction of 1,4-dioxane agonists at the M2 and M3 muscarinic receptor orthosteric sites.
AID9454Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.
AID125479Peripheral muscarinic effect was evaluated in mice by intravenous injection; No visible tremors or salivation observed1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Tertiary 2-haloethylamine derivatives of the muscarinic agent McN-A-343, [4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium chloride.
AID1181730Displacement of [3H]NMS from human muscarinic M1 receptor transfected in CHO cells after 120 mins by scintillation counting analysis2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Mode of interaction of 1,4-dioxane agonists at the M2 and M3 muscarinic receptor orthosteric sites.
AID142862In vivo determination of peripheral M2 receptor mediated tremor, cholinergic side effect1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity.
AID1072498Intrinsic activity at muscarinic M1 receptor in New Zealand rabbit vas deferens assessed as stimulation of electrically-induced response relative to McN-A-3432014European journal of medicinal chemistry, Mar-21, Volume: 75Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity.
AID454116Displacement of [3H]NMS from human muscarinic M3 receptor expressed in CHO cells by microplate scintillation counting2009Bioorganic & medicinal chemistry, Dec-15, Volume: 17, Issue:24
Properly substituted 1,4-dioxane nucleus favours the selective M3 muscarinic receptor activation.
AID1147916Ganglion-stimulant activity in cat assessed as pressor response up to 1000 ug/kg, iv1976Journal of medicinal chemistry, Jan, Volume: 19, Issue:1
Stereochemical analogs of a muscarinic, ganglionic stimulant. 3. 2,3-Substituted bicyclo(2.2.1)hept-5-enes and -heptanes related to 4-(N-(3-chlorophenyl)carbamoyloxy)-2-butynyltrimethylammonium chloride (McN-A-343).
AID141559In vitro binding affinity against muscarinic acetylcholine receptor M1 from rat hippocampus, using [3H]oxotremorine-M (Oxo-M) as radioligand1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .
AID9455Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.
AID141575Binding activity against muscarinic acetylcholine receptor M1 in rat brain, using [3H]-Pz as the radioligand.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1181733Displacement of [3H]NMS from human muscarinic M4 receptor transfected in CHO cells after 120 mins by scintillation counting analysis2014Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15
Mode of interaction of 1,4-dioxane agonists at the M2 and M3 muscarinic receptor orthosteric sites.
AID142861In vivo determination of peripheral M2 receptor mediated salivation, cholinergic side effect1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity.
AID454117Displacement of [3H]NMS from human muscarinic M4 receptor expressed in CHO cells by microplate scintillation counting2009Bioorganic & medicinal chemistry, Dec-15, Volume: 17, Issue:24
Properly substituted 1,4-dioxane nucleus favours the selective M3 muscarinic receptor activation.
AID134726Lethal dose was determined in male Swiss-Webster mice by intravenous injection using up-and-down method1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Tertiary 2-haloethylamine derivatives of the muscarinic agent McN-A-343, [4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]trimethylammonium chloride.
AID302025Intrinsic activity at muscarinic M1 receptor in electrically stimulated New Zealand rabbit vas deferens relative to McN-A-3432007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Novel oxotremorine-related heterocyclic derivatives: Synthesis and in vitro pharmacology at the muscarinic receptor subtypes.
AID142741M2 agonist activity estimated by depression of isolated guinea pig left atrium1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity.
AID78308In vitro inhibition of force of contraction in guinea pig atria.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .
AID167827In vitro inhibition of twitch height in electrically stimulated rabbit vas deferens1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .
AID141574Binding activity against muscarinic acetylcholine receptor M1 in rat brain, using [3H]OXO-M as the radioligand.1995Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18
Functionally selective M1 muscarinic agonists. 3. Side chains and azacycles contributing to functional muscarinic selectivity among pyrazinylazacycles.
AID1072494Inhibition of acetylcholinesterase in rat brain homogenate after 15 mins by Ellman assay relative to control2014European journal of medicinal chemistry, Mar-21, Volume: 75Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity.
AID78185In vitro inhibition of maximum force of contraction in guinea pig atria.1992Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12
Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines .
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID454120Agonist activity at muscarinic M1 receptor in New Zealand White rabbit vas deferens assessed as inhibition of electrically-stimulated muscle contraction2009Bioorganic & medicinal chemistry, Dec-15, Volume: 17, Issue:24
Properly substituted 1,4-dioxane nucleus favours the selective M3 muscarinic receptor activation.
AID142859In vivo determination of peripheral M2 receptor mediated hypothermia, cholinergic side effect1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity.
AID142613M1 agonist activity estimated by rat superior cervical ganglion depolarization1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles. Synthesis and muscarinic activity.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1345543Human M5 receptor (Acetylcholine receptors (muscarinic))1995British journal of pharmacology, Mar, Volume: 114, Issue:6
Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists.
AID1345189Rat M1 receptor (Acetylcholine receptors (muscarinic))1989The Journal of pharmacology and experimental therapeutics, Feb, Volume: 248, Issue:2
Pharmacological characterization of the M1 muscarinic receptors expressed in murine fibroblast B82 cells.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))1995British journal of pharmacology, Mar, Volume: 114, Issue:6
Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists.
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))1995British journal of pharmacology, Mar, Volume: 114, Issue:6
Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))1993Life sciences, , Volume: 52, Issue:5-6
New functionally selective muscarinic agonists.
AID1345364Rat M2 receptor (Acetylcholine receptors (muscarinic))1993Life sciences, , Volume: 52, Issue:5-6
New functionally selective muscarinic agonists.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (281)

TimeframeStudies, This Drug (%)All Drugs %
pre-199085 (30.25)18.7374
1990's132 (46.98)18.2507
2000's39 (13.88)29.6817
2010's21 (7.47)24.3611
2020's4 (1.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.69 (24.57)
Research Supply Index5.66 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (1.40%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other281 (98.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]